What Panastat Treats: Main Uses and Benefits

Panastat (Itraconazole) is a systemic antifungal medicine commonly applied across domains where additional symptomatic support is needed to address significant fungal infections throughout the body. The medication is considered relevant for easing symptoms that become more disruptive during flare-ups and that create noticeable physiological strain.

---

Key Therapeutic Applications

Panastat is generally used to address serious systemic mycoses, such as Aspergillosis, Histoplasmosis, and Blastomycosis, which cause symptoms related to systemic imbalance like persistent fevers and chronic pulmonary symptoms. The primary therapeutic role is focused on managing the invasive pathogen. The medicine is also relevant for managing chronic fungal infections affecting the appendages, like onychomycosis (nail fungus), and the mucosal linings, such as esophageal candidiasis.

The medication is applied in addressing conditions involving inflammatory or irritative processes, which helps to relieve acute symptoms, including difficulty swallowing (dysphagia). This provides supportive relief and contributes to maintaining functional stability. For high-risk, immunocompromised individuals, the medicine is applied to offer crucial preventive support, contributing to easing the overall symptom load.

“This medication supports the patient during difficult episodes by easing distress related to organ-specific functional stress.”

---

Quick Fact: Relief for Fungal Discomfort

Therapeutic Benefit	Conditions Managed	Symptom Focus
Systemic Support	Deep-seated mycoses (e.g., Histoplasmosis)	Persistent fevers, chronic pulmonary symptoms
Mucosal Relief	Esophageal candidiasis	Difficulty swallowing (Dysphagia), pain, inflammation
Appendage Health	Onychomycosis	Nail discoloration, thickening, structural strain

Regulatory References

1. NIH MedlinePlus overview of Itraconazole uses

Official Eligibility and Non-Eligibility Status

The eligibility profile for Panastat (Itraconazole) is defined by mandatory exclusions and restricted-use classifications outlined in regulatory documents.

Classification	Official Regulatory Status
Contraindicated Populations	Patients with known hypersensitivity to the drug or its components. Pregnant women, except for life-threatening systemic infections. Patients with ventricular dysfunction or a history of congestive heart failure (CHF) for non-life-threatening indications [Source 1.5, 2.7].
Age-Related Rules	Pediatric Use: Safety and efficacy are not established in patients under 18 years of age. Older Adults: Use requires caution due to a higher likelihood of decreased cardiac, renal, or hepatic function [Source 1.1, 1.4].
Conditional Use Required	Patients with renal impairment or hepatic impairment must be treated with caution and monitoring. Use in active liver disease is strongly discouraged for non-life-threatening cases [Source 1.2, 3.2]. Women of childbearing potential must use effective contraception during and for two months following therapy [Source 1.5].
Not Recommended	Breastfeeding is not recommended as the drug is excreted in human milk [Source 1.1].

The official label mandates non-use for patients with specific cardiovascular and hypersensitivity conditions, while establishing use with caution classifications for patients with impaired organ function. Regulatory documents state that safety and efficacy have not been established in the pediatric population, thereby limiting their eligibility for treatment.

Panastat (Itraconazole) has officially documented interaction patterns that are primarily governed by its effect on drug metabolism and absorption. The medication acts as a potent inhibitor of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). This interaction leads to increased plasma concentrations of co-administered medicines that are metabolized by these pathways.

Because of this risk, official regulatory labeling formally contraindicates the combination of Panastat with several classes of drugs, including specific HMG-CoA reductase inhibitors and antiarrhythmics, as well as ergot alkaloids, due to the potential for severe or life-threatening toxic reactions.

Conversely, the co-administration of Panastat with strong CYP3A4 inducers (such as rifampicin) or herbal products like St. John’s Wort is prohibited because these substances significantly reduce Itraconazole plasma concentrations, leading to subtherapeutic exposure. The drug’s absorption is also highly dependent on gastric acidity. As a result, when taking the capsule formulation, acid-reducing medicines (like antacids) must be administered at least 2 hours after Panastat to avoid reduced exposure. Furthermore, the administration requirements are formulation-specific: the capsule requires administration with a meal for optimal absorption, while the oral solution must be taken without food. These documented constraints define the boundaries for co-administration.

Targeted Molecular Inhibition of Fungal Enzymes

The action of Panastat is initiated by selective engagement with the fungal enzyme Cytochrome P450 14alpha-demethylase (CYP51). The molecule blocks this enzyme via coordinate bonding to the heme iron atom, inhibiting a necessary early molecular step in the pathogen's metabolic pathway. This targeted molecular inhibition directly prevents the conversion of lanosterol into essential sterols.

---

Disruption of Fungal Cell Membrane Structure

The cessation of CYP51 activity causes the physiological effect of Ergosterol deprivation. This essential structural molecule is replaced by abnormal, toxic sterol precursors, leading to a compromised cell membrane with altered permeability and rigidity. This structural failure causes the leakage of intracellular components and functional collapse, resulting in diminished fungal growth and compromised cell viability.

---

️ Constraint by Pathogen Resistance Mechanisms

The ability of the mechanism to function is constrained by fungal adaptive processes, primarily the genetic modification or overexpression of the CYP51 target enzyme and the activity of specialized efflux pumps. These mechanisms reduce the drug's effective intracellular concentration or its binding affinity, which limits the complete inhibition of the enzyme and may reduce the resulting physiological disruption of the fungal pathogen.

Official Administration Guidelines

Panastat (Itraconazole) is approved for oral administration across its available formulations, which include capsules and a solution. Dosage and administration procedures are dependent on the specific formulation and the duration of therapy.

Dosing Patterns and Frequency

Treatment regimens vary significantly. For severe systemic fungal infections, a loading dose of 200 mg three times daily is typically administered for the first three days, followed by a maintenance dose ranging from 200 mg once or twice daily. Conditions like onychomycosis are treated with either a continuous regimen (200 mg once daily for 12 consecutive weeks) or a pulsed regimen, consisting of 200 mg twice daily for one week, followed by a drug-free period of three weeks, and then repeated for a second cycle.

Administration Specifics

Formulation	Administration Rule	Purpose
Oral Capsule/Tablet	Must be taken immediately after a full meal.	To ensure maximal absorption and bioavailability.
Oral Solution	Must be taken on an empty stomach.	To optimize absorption for the liquid formulation.

Crucially, the capsule and oral solution are not interchangeable at the same dose due to differences in systemic exposure. Capsules must be swallowed whole. For the oral solution when treating candidiasis of the mouth, the liquid should be swished vigorously in the oral cavity for several seconds before swallowing. Dose adjustments are considered for patients with hepatic or renal impairment and in older adults, reflecting a greater frequency of decreased organ function. If a dose is missed, standard protocols involve taking the missed dose as soon as remembered unless it is near the time of the next dose, at which point the missed dose is skipped to avoid a double dose.

Panastat: Recent Clinical Evidence

---

Evidence for Systemic and Preventive Use

Research has explored Panastat's role in serious systemic fungal infections (like Histoplasmosis and Blastomycosis) and its use in prophylaxis (prevention) for high-risk, immunocompromised adults. For systemic infections, research includes historical prospective trials and observational studies that track clinical status and long-term outcomes, with findings describing patterns observed in the studies. For prophylaxis, randomized, placebo-controlled trials (RCTs) were designed to monitor the time interval until a specific fungal infection occurred. These studies documented observations where the number of specific fungal infections differed between the study group and those receiving a placebo. However, some trials reported that the medicine was not associated with a measurable difference in overall patient survival.

---

Evidence for Appendages and Mucosa

For Onychomycosis (nail fungus), research involves Phase 3 RCTs and meta-analyses that track outcomes like fungal clearance and visual changes. Findings describe patterns where clearance was documented, but research highlights that high rates of fungal recurrence and persistence was observed in some studies in the long term. For Mucosal Candidiasis, short-term randomized trials evaluated acute symptom resolution. Clinical relapse was observed in some studies soon after treatment ended, especially in patients with high levels of immunosuppression.

---

Evidence Landscape and Limitations

The evidence base specifically includes studies on immunocompromised adults and describes different disease severity strata. However, data for certain groups (such as pediatric patients or pregnant individuals) remain insufficient or limited. Overall, evidence quality varies across studies due to reliance on older observational methodologies for some indications, and long-term outcomes are not fully established for all uses due to limited follow-up durations in certain trials. The evidence landscape would benefit from further research to provide insight into long-term changes.

Key Studies & References

1. Itraconazole Drug Information: Uses, Dosage, Side Effects, Interactions

Common questions about Panastat (FAQ)

---

Q: Is there a generic version of Panastat available?

A: Yes. Panastat is the brand name for the medicine with the generic name Itraconazole. Official sources and manufacturer information confirm that generic versions of Itraconazole are widely available.

Q: Can Panastat be crushed or split?

A: Official administration guidelines for the Panastat capsule state that it must be swallowed whole. This administration requirement is intended to support appropriate drug absorption.

Q: Does Panastat cause weight gain or loss?

A: Weight changes are not typically listed as common side effects of Panastat in regulatory documents. However, official safety warnings describe that rapid, unexplained weight gain can be a documented sign of congestive heart failure. This type of symptom is described as serious and warrants discussion with a healthcare provider.

Q: Why do some people experience fatigue when taking Panastat?

A: Fatigue is documented in some regulatory summaries as a common adverse effect. Additionally, unusual or sudden fatigue is listed in safety information as a potential symptom of heart failure, which is a rare but serious safety concern associated with Panastat. Such a symptom warrants discussion with a healthcare provider.

Q: What are the signs of a serious allergic reaction to Panastat?

A: The official product information describes signs of a serious allergic reaction, also known as hypersensitivity. These may include having difficulty breathing, shortness of breath, or swelling of the face, lips, tongue, or other body parts.

Q: Does Panastat have any known sexual side effects?

A: Some infrequent adverse effects reported in post-marketing or regulatory summaries include certain sexual side effects. These have included reports of gynecomastia (enlargement of male breast tissue) and impotence.

Q: What percentage of people report experiencing a certain side effect from Panastat?

A: Official information generally describes side effects using broad terms like 'common,' 'uncommon,' or 'rare'. While regulatory documents may include specific frequency tables, precise patient-specific percentages for every single adverse event are not typically summarized in patient-facing materials.

Q: What should I know about Panastat and alcohol?

A: Official drug labels do not always contain specific alcohol contraindications, but some patient information provided by institutions advises avoiding alcohol while taking this medicine. Official guidance emphasizes the importance of understanding the risks before combining this medicine with alcohol.

Q: Does Panastat interact with grapefruit or grapefruit juice?

A: Yes, official studies indicate that grapefruit juice can interfere with the way Panastat capsules are absorbed by the body. This interaction can reduce the amount of medicine that gets into the blood. Therefore, consumption of grapefruit or grapefruit juice is generally discouraged while using Panastat.

Q: Is Panastat safe for use in children?

A: Official documents and research summaries state that the data for using Panastat in pediatric patients remains insufficient or limited. However, use may be considered for specific severe infections or prevention in children aged two years and older.

Q: What should be monitored while a person is taking Panastat?

A: Regulatory information advises that patients taking Panastat for one month or longer should have certain biological functions monitored. This generally includes monitoring parameters such as renal function, hepatic function, complete blood count, and potassium levels.

Q: Do studies suggest Panastat loses effectiveness over time?

A: Research evidence highlights that for some conditions, like nail fungus and mouth candidiasis, fungal recurrence or persistence has been observed after treatment has concluded. This suggests that long-term follow-up is relevant to observing outcomes.

Q: How quickly is Panastat expected to start working?

A: The time frame for therapeutic outcomes can vary depending on the specific condition. The medicine reaches its highest concentration in the blood within a few hours after a dose. Full steady-state levels (a stable concentration in the body) are typically reached after about 15 days of continuous dosing.

Q: Are there specific food restrictions when taking Panastat?

A: Yes, administration rules are formulation-specific. The capsule must be taken with a full meal, but the oral solution is generally administered without food. Certain substances, such as grapefruit juice and acid-reducing medicines, can also affect how much medicine the body absorbs.

Q: Is Panastat available without a prescription?

A: Panastat (Itraconazole) is formally classified as a prescription-only medication. It is a potent antifungal medicine and is not available for purchase over the counter.

Q: What is the chemical name for Panastat?

A: The generic name for Panastat is Itraconazole. The full chemical name is a complex technical term used to define the molecule's structure. The generic and brand names are the primary identifiers used for prescribing and patient identification.

Q: Is Panastat related to 'Statin' drugs?

A: Panastat is classified as an antifungal medicine and is chemically different from 'statin' drugs, which are used to manage cholesterol. However, Panastat can significantly affect the levels of some statin medicines in the body, which is why many of them are formally contraindicated (prohibited) for use at the same time.

Q: Can Panastat be used long-term?

A: The duration of treatment is specific to the fungal condition being treated, ranging from several weeks to several months. Panastat is typically prescribed for defined periods, and safety information for use exceeding six months is limited for some formulations.

Q: What is the legal classification of Panastat in the US (e.g., Schedule)?

A: Official regulatory information confirms that Panastat (Itraconazole) is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: What is the difference between the brand name and the generic name of Panastat?

A: Panastat is the brand name chosen by the original manufacturer. The generic name for the active ingredient is Itraconazole. Regulatory agencies require both names to be identified on official labeling for proper product identification.

Q: Does Panastat affect blood pressure?

A: While it is not listed as a common side effect, some cases of high blood pressure (hypertension) have been reported in the post-marketing experience with Panastat. Close monitoring of blood pressure may be advised during therapy.

Q: Does Panastat interact with vitamins or supplements?

A: Panastat is formally contraindicated with certain strong enzyme-inducing herbal products like St. John's Wort. It can also interact with medicines that affect stomach acidity, which may be present in certain supplements. General information about every supplement is not detailed in regulatory documents.

Q: Can people with a lactose intolerance take the Panastat tablet?

A: Official manufacturer information confirms that the capsule formulation contains sucrose (sugar) as an inactive ingredient. The full list of excipients (inactive ingredients), including the potential presence of lactose in specific tablet formulations, is detailed in the manufacturer's official Patient Information Leaflet or Summary of Product Characteristics (SmPC).

Q: Do patients generally need to take Panastat forever?

A: The duration of treatment with Panastat is highly specific to the infection being addressed and is generally for a defined period, ranging from weeks to months. It is not generally intended to be a medicine taken for the rest of a patient's life.

Q: Does Panastat need to be refrigerated?

A: The standard capsule and tablet formulations are typically advised to be stored at controlled room temperature, meaning between 15 C and 25 C. However, specific liquid formulations may have different requirements, which will be detailed on the packaging.

Q: Are there official patient education guides for Panastat?

A: Yes, official patient education materials and drug information sheets are created by the manufacturer and provided through government authorities, such as the FDA and NIH. These are generally included with the dispensed medicine.

Q: Can Panastat affect the results of blood tests?

A: Yes, regulatory information advises that certain blood tests should be monitored regularly during treatment with Panastat. These tests specifically check for proper functioning of the liver and kidneys, and also look at potassium levels.

How to Store and Dispose of Panastat (Itraconazole)

Panastat must be stored at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). The product must be protected from moisture and stored in its original, tightly closed container.

---

Required Handling and Disposal

Official labeling strictly prohibits refrigerating or freezing the medication to maintain stability. The medicine must also be stored out of the sight and reach of children.

For disposal, unused or expired Panastat must not be placed into household waste or wastewater. It is required to dispose of the product in accordance with local pharmaceutical waste regulations.